Pharma BD Deal Intelligence
Global generics consolidation succeeded operationally but fed destructive acquisition cycle
Full analysis, sources & comparables →Teva acquired Barr Pharmaceuticals for $7.5B including PLIVA operations.
FTC intervenes in Teva's proposed $8.9 billion acquisition of Barr Pharmaceuticals, requiring the sale of assets in 29 U.S. markets covering 17 generic…
Teva completes the acquisition of Barr Pharmaceuticals in an $8.9 billion deal, with shareholders receiving $39.90 in cash and 0.6272 Teva ADSs per Barr share,…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Teva Pharmaceutical Industries acquired Barr Pharmaceuticals for $39.90 cash plus 0.6272 Teva ADRs per share (~$7.5 billion equity value plus $1.5 billion assumed debt), gaining Barr's US generics portfolio including first-to-file ANDA positions, PLIVA's European operations, and a growing women's health branded portfolio (Plan B, Seasonique).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Teva Pharmaceutical Industries Ltd. / Barr Pharmaceuticals (this deal) | 2008 | $7.5B | 58 |
| Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals | 2015 | $3.5B | 86 |
| Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical | 1995 | — | 82 |
| Teva Pharmaceutical Industries Ltd. / Sicor Inc. | 2003 | $3.4B | 68 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2006 | $7.4B | 63 |
| Teva Pharmaceutical Industries Ltd. / Novopharm Limited | 2000 | $600M | 62 |
| Teva Pharmaceutical Industries Ltd. / Ivax Corporation | 2005 | $7.4B | 62 |
← Browse all deals · How we score deals
More: 2008 deals · Teva Pharmaceutical Industries Ltd. deals · Neurology deals